ervebo
merck sharp & dohme b.v. - skal læknir hafa blöðrum bólgur veira (álag indiana) með eyðingu umslagið glýkóprótein, komi með zaire ebolavirus (álag kikwit 1995) yfirborðið glýkóprótein - blæðandi hiti, ebóla - bóluefni - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. notkun ervebo ætti að vera í samræmi við opinbera tillögur.
cutaquig stungulyf, lausn 165 mg/ml
octapharma ab - immunoglobulinum humanum inn - stungulyf, lausn - 165 mg/ml
mycofenolsýra accord (mycofenolsýra accord healthcare) magasýruþolin tafla 180 mg
accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 180 mg
mycofenolsýra accord (mycofenolsýra accord healthcare) magasýruþolin tafla 360 mg
accord healthcare b.v. - mycophenolatum natríum - magasýruþolin tafla - 360 mg
nanogam innrennslislyf, lausn 50 mg/ml
prothya biosolutions netherlands b.v. - immunoglobulinum humanum inn - innrennslislyf, lausn - 50 mg/ml
tyruko
sandoz gmbh - natalízúmab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.